Gallagher Neil 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 7, 2025
Insider Transaction Report
Form 4
Gallagher Neil
President, Head of R&D
Transactions
- Award
Stock Options (Right to buy)
2025-02-05$14.65/sh+110,500$1,618,825→ 110,500 totalExercise: $14.65Exp: 2035-02-05→ Common Stock (110,500 underlying) - Award
Common Stock
2025-02-05+18,500→ 66,313 total - Award
Common Stock
2025-02-05+23,400→ 89,713 total
Footnotes (3)
- [F1]Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.
- [F2]Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.
- [F3]1/48th of the shares subject to the option shall vest monthly over a four-year period.